239 related articles for article (PubMed ID: 27358579)
1. Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2.
Kim C; Lee HJ; Masliah E; Lee SJ
Exp Neurobiol; 2016 Jun; 25(3):113-9. PubMed ID: 27358579
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.
Kim C; Spencer B; Rockenstein E; Yamakado H; Mante M; Adame A; Fields JA; Masliah D; Iba M; Lee HJ; Rissman RA; Lee SJ; Masliah E
Mol Neurodegener; 2018 Aug; 13(1):43. PubMed ID: 30092810
[TBL] [Abstract][Full Text] [Related]
3. Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies.
Kwon S; Iba M; Masliah E; Kim C
Exp Neurobiol; 2019 Oct; 28(5):547-553. PubMed ID: 31698547
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology.
Dzamko N; Gysbers A; Perera G; Bahar A; Shankar A; Gao J; Fu Y; Halliday GM
Acta Neuropathol; 2017 Feb; 133(2):303-319. PubMed ID: 27888296
[TBL] [Abstract][Full Text] [Related]
5. Non-cell-autonomous actions of α-synuclein: Implications in glial synucleinopathies.
Lim S; Kim HJ; Kim DK; Lee SJ
Prog Neurobiol; 2018 Oct; 169():158-171. PubMed ID: 30173732
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies.
Kim C; Beilina A; Smith N; Li Y; Kim M; Kumaran R; Kaganovich A; Mamais A; Adame A; Iba M; Kwon S; Lee WJ; Shin SJ; Rissman RA; You S; Lee SJ; Singleton AB; Cookson MR; Masliah E
Sci Transl Med; 2020 Oct; 12(565):. PubMed ID: 33055242
[TBL] [Abstract][Full Text] [Related]
7. Reactive microglia enhance the transmission of exosomal α-synuclein via toll-like receptor 2.
Xia Y; Zhang G; Kou L; Yin S; Han C; Hu J; Wan F; Sun Y; Wu J; Li Y; Huang J; Xiong N; Zhang Z; Wang T
Brain; 2021 Aug; 144(7):2024-2037. PubMed ID: 33792662
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein biology in Lewy body diseases.
Kim WS; Kågedal K; Halliday GM
Alzheimers Res Ther; 2014; 6(5):73. PubMed ID: 25580161
[TBL] [Abstract][Full Text] [Related]
9. The Role of Glial Mitochondria in α-Synuclein Toxicity.
Jeon YM; Kwon Y; Jo M; Lee S; Kim S; Kim HJ
Front Cell Dev Biol; 2020; 8():548283. PubMed ID: 33262983
[TBL] [Abstract][Full Text] [Related]
10. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia.
Lee HJ; Suk JE; Bae EJ; Lee SJ
Biochem Biophys Res Commun; 2008 Aug; 372(3):423-8. PubMed ID: 18492487
[TBL] [Abstract][Full Text] [Related]
11. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein activates BV2 microglia dependent on its aggregation state.
Hoffmann A; Ettle B; Bruno A; Kulinich A; Hoffmann AC; von Wittgenstein J; Winkler J; Xiang W; Schlachetzki JCM
Biochem Biophys Res Commun; 2016 Oct; 479(4):881-886. PubMed ID: 27666480
[TBL] [Abstract][Full Text] [Related]
13. Neuropathological spectrum of synucleinopathies.
Jellinger KA
Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
[TBL] [Abstract][Full Text] [Related]
14. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.
Lee SJ
J Mol Neurosci; 2008; 34(1):17-22. PubMed ID: 18157654
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
16. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia.
Kim C; Ho DH; Suk JE; You S; Michael S; Kang J; Joong Lee S; Masliah E; Hwang D; Lee HJ; Lee SJ
Nat Commun; 2013; 4():1562. PubMed ID: 23463005
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
18. Neuroinflammation Upregulated Neuronal Toll-Like Receptors 2 and 4 to Drive Synucleinopathy in Neurodegeneration.
Chung LY; Lin YT; Liu C; Tai YC; Lin HY; Lin CH; Chen CC
Front Pharmacol; 2022; 13():845930. PubMed ID: 35401198
[No Abstract] [Full Text] [Related]
19. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein.
Jin J; Shie FS; Liu J; Wang Y; Davis J; Schantz AM; Montine KS; Montine TJ; Zhang J
J Neuroinflammation; 2007 Jan; 4():2. PubMed ID: 17204153
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
